Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer

被引:34
|
作者
Brown, T. [1 ]
Boland, A. [1 ]
Bagust, A. [1 ]
Oyee, J. [1 ]
Hockenhull, J. [1 ]
Dundar, Y. [1 ]
Dickson, R. [1 ]
Ramani, V. S. [1 ]
Proudlove, C. [1 ]
机构
[1] Univ Liverpool, Liverpool Reviews & Implementat Grp, Liverpool L69 3GB, Merseyside, England
关键词
D O I
10.3310/hta14suppl2/10
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in accordance with the licensed indication, based upon the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. The submitted clinical evidence consisted of the IRESSA Pan-ASian Study (IPASS); a phase III open-label randomised controlled trial conducted in 87 centres in East Asia which compared the use of gefitinib with paclitaxel/carboplatin in 1217 chemotherapy (CTX)-naive patients with stage IIIB/IV pulmonary adenocarcinoma. The manufacturer's submission focused on a subgroup of patients in IPASS who were epidermal growth factor receptor (EGFR) gene mutation-positive (M+) (n = 261; 21% of the total IPASS population). The primary clinical outcome was progression-free survival (PFS). Secondary outcomes included overall survival, clinically relevant improvement in quality of life and adverse events (AEs). Cost-effectiveness was measured in terms of incremental cost per quality-adjusted life-year (QALY). In the overall population, PFS was significantly longer in patients treated with gefitinib than in those treated with paclitaxel/carboplatin (hazard ratio 0.74, 95% confidence interval 0.65 to 0.85; p < 0.0001). The manufacturer reported an incremental cost-effectiveness ratio (ICER) of 20,744 pound per QALY gained for the target population. The probabilistic sensitivity analysis illustrated that for patients who are EGFR M+, gefitinib compared with doublet CTX was not likely to be cost-effective at what would usually be considered standard levels of willingness to pay for an additional QALY; the mean ICER for gefitinib EGFR M+ versus doublet CTX EGFR M+ was reported as 35,700 pound per QALY. Additional analysis by the ERG included amendments to the base-case analysis, including an alternative approach to projecting survival, inclusion of two important additional comparators, sensitivity to EGFR M+ prevalence, and AE costs and disutilities. The manufacturer's submission provides clinical evidence to support the use of gefitinib in EGFR M+ patients with adenocarcinoma histology only. Before patients can be offered first-line treatment with gefitinib they must undergo EGFR mutation status testing which is currently not routinely available in the NHS. At the time of writing, the guidance document issued by NICE on 28 July 2010 states that 'Gefitinib is recommended as an option for the first-line treatment of people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) if they test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme'.
引用
收藏
页码:71 / 79
页数:9
相关论文
共 50 条
  • [41] Predictive model for response to first-line treatment for metastatic non-small cell lung cancer.
    Badawy, Ahmed Ashour
    Bae, Sejong
    Omar, Abbas
    Arafat, Waleed O.
    Khedr, Gehan Abd Elatti
    Grant, Stefan C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Dane, Faysal
    Isikdogan, Abdurrahman
    Ustaalioglu, Basak Oven
    Coskun, Ugur
    Yumuk, Perran Fulden
    Dogu, Gamze Gokoz
    Ozdemir, Nuriye Yildirim
    Sevinc, Alper
    Gumus, Mahmut
    Ozkan, Metin
    Yildiz, Ramazan
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    [J]. TUMORI JOURNAL, 2010, 96 (03): : 400 - 404
  • [43] Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer
    Stares, Mark
    Swan, Amanda
    Cumming, Kirsten
    Ding, Tze-En
    Leach, James
    Stratton, Cory
    Thomson, Findlay
    Barrie, Colin
    MacLennan, Kirsty
    Campbell, Sorcha
    Evans, Tamasin
    Tufail, Aisha
    Harrow, Stephen
    MacKean, Melanie
    Phillips, Iain
    [J]. FRONTIERS IN NUTRITION, 2021, 8
  • [44] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [45] Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
    Rauthan, A.
    Patil, P.
    Lahkar, K.
    Murthy, N. Y.
    Vundemodalu, P.
    Ashwath, R.
    Jomi, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1576 - S1576
  • [46] Effectiveness and cost of gefitinib in advanced/metastatic non-small cell lung cancer
    Selvi-Sabater, P.
    Sanchez-Martinez, I.
    Sadyrbaeva-Dolgova, S.
    Portillo-Haro, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 289 - 289
  • [47] Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
    Greenhalgh, J.
    McLeod, C.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    Dundar, Y.
    Oyee, J.
    Dickson, R.
    Davis, H.
    Green, J.
    McKenna, E.
    Pearson, M.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 33 - 39
  • [48] Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer
    Leow, CH
    Liam, CK
    [J]. RESPIROLOGY, 2005, 10 (05) : 629 - 635
  • [49] First-line management of metastatic non-small cell lung cancer: An Indian perspective
    Ghadyalpatil, Nikhil Suresh
    Pandey, Avinash
    Krishnamani, Iyer
    Srinivas, Chilukuri
    Rafiq, Shabnam J.
    Hingmire, Sachin S.
    Maturu, Nagarjuna
    Reddy, Ragotham
    Kumar, Kiran K.
    Sreekanth, K.
    Gurram, Bharath Chandra
    Parikh, P. M.
    [J]. SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (02) : 73 - +
  • [50] First-line Oral Vinorelbine for Elderly or Unfit Patients With Advanced/metastatic Non-small Cell Lung Cancer
    Mansueto, G.
    Longo, F.
    Stumbo, L.
    De Filippis, L.
    Del Signore, E.
    Quadrini, S.
    Del Bene, G.
    Adua, D.
    Lapadula, V.
    Di Seri, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S280 - S280